WHAT YOU NEED TO KNOW CAPA Stresses Importance Of Next USPTO Director – This week, CAPA Executive Director Matthew Lane penned an op-ed in STAT News highlighting the crucial role that the next U.S. Patent and Trademark Office Director will have on reducing drug costs for millions of American patients, many of which are already struggling financially […]

Continue Reading

IN CASE YOU MISSED IT: Today, STAT News published an op-ed by Matthew Lane, executive director of the Coalition Against Patent Abuse (CAPA), highlighting the crucial role that the next U.S. Patent and Trademark Office (USPTO) director will have on reducing drug costs for millions of American patients, many of which are already struggling financially due to […]

Continue Reading

Part III: IPR & Opioid Addiction – Ending Brand Pharma’s Monopoly on Patents Some major pharmaceutical companies have enormous incentives to block market entry of lower-cost, generic drugs for as long as possible.  By taking advantage of certain rules or exploiting legal loopholes that extend a drug’s monopoly far beyond what Congress intended, millions of […]

Continue Reading